Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1641398 | 0.85 | ALOX5AP (0.36) | HRH3FTO | |
| SCHEMBL1640024 | 0.82 | KCNH2 (0.36) | HRH3KCNH2CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL17428939 | 0.81 | KMT2A (0.41) | HDAC4HDAC1HDAC6 | |
| SCHEMBL1640385 | 0.80 | CLK4 (0.36) | HRH3CYP19A1CYP11B1CYP11B2MAOB | |
| SCHEMBL1640249 | 0.77 | KCNH2 (0.39) | WNT3AHRH3KCNH2CYP19A1CYP11B1 | |
| SCHEMBL1641029 | 0.76 | ADRB2 (0.42) | HRH3KCNH2 | |
| SCHEMBL1641298 | 0.76 | CA12 (0.35) | — | |
| SCHEMBL1641452 | 0.76 | CDK8 (0.43) | WNT3AHRH3KCNH2CYP19A1CYP11B1 | |
| SCHEMBL1641359 | 0.74 | NPC1 (0.35) | MAOBCYP17A1 | |
| SCHEMBL1641411 | 0.74 | MAOB (0.34) | HRH3KCNH2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273767-B2 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2012-09-25 | — | — | US | disclosed |
| US-7947711-B2 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110098285-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-04-28 | — | — | US | disclosed |
| US-20090054420-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | disclosed |
| US-7456196-B2 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2008-11-25 | — | — | US | disclosed |
| US-7153889-B2 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060194798-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2006-08-31 | — | — | US | disclosed |
| EP-1569637-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | Abbott Laboratories (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040152704-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004043458-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098285-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | HRH3, HRH4, HRH2 | WNT3A 1941/4885HRH3 1/4885KCNH2 1032/4885 |
| US-20060194798-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH2 | WNT3A 1941/4885HRH3 1/4885KCNH2 1032/4885 |
| US-20090054420-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | HRH3, HRH4, HRH2 | WNT3A 1941/4885HRH3 1/4885KCNH2 1032/4885 |
| US-20040152704-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | WNT3A 2269/4885HRH3 1/4885KCNH2 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.